Core Insights - Smith + Nephew (SNN) has formed a strategic partnership with Standard Health to establish the UK's first dedicated Orthopaedic Ambulatory Surgery Centre (ASC) in Poole, Dorset, aimed at transforming outpatient orthopedic care [1][4][6] - The collaboration combines SNN's innovative surgical solutions with Standard Health's clinical expertise to enhance patient outcomes and reduce surgical wait times [2][4] - SNN's market capitalization stands at $12.52 billion, with projected fiscal 2025 revenues of $6.12 billion, indicating a growth of 10.3% from fiscal 2023 [5] Company Developments - The new ASC will focus on minimally invasive procedures, including rotator cuff repairs, ACL reconstructions, and joint replacements, catering to both NHS and private patients [1][7] - SNN is positioned to capitalize on the growing trend towards outpatient orthopedic procedures, enhancing its presence in the ASC market and driving adoption of its surgical technologies [4][9] - Standard Health plans to expand to 20 ASC sites across the UK by 2030, providing SNN with scalable opportunities to deepen its market presence [6][9] Industry Trends - The global ambulatory surgery centers market is projected to grow from $134.9 billion in 2023 to $205.5 billion by 2030, with a CAGR of 6.2% from 2024 to 2030, driven by a shift of surgical procedures from hospitals to ASCs [10] - The ASC model has shown greater procedural efficiency and patient satisfaction, making it an attractive alternative to traditional hospital settings [8][10] - With over 850,000 patients awaiting orthopedic surgeries in the UK, the NHS is increasingly relying on independent providers to alleviate backlogs, indicating a strong demand for SNN's services [9]

Core Viewpoint - McKesson Corporation plans to spin off its Medical-Surgical Solutions segment into an independent company, referred to as NewCo, to enhance shareholder value and focus on strategic growth priorities in its remaining segments [1][2][4]. Deal Overview - The spin-off is part of McKesson's disciplined portfolio management strategy, which has previously included significant divestitures that unlocked shareholder value [2]. - The Medical-Surgical Solutions segment accounts for only 3.2% of McKesson's total revenue, with FY25 revenue around $11.4 billion, and has experienced sluggish growth since 2020 [4][17]. Financial Performance - For FY25, McKesson reported consolidated revenues of $359.1 billion, a 16.2% increase year-over-year from $309.0 billion in FY24 [12]. - In 4Q25, revenues reached $90.8 billion, up 18.9% year-over-year, driven by growth in the U.S. Pharmaceutical segment [10]. - Net income for FY25 was $3.3 billion, a 9.8% increase year-over-year, while adjusted net income was $4.2 billion, up 15.1% [12]. Strategic Focus Post-Spin-Off - After the spin-off, McKesson will concentrate on higher growth and higher margin opportunities in Oncology and Biopharma Solutions [3]. - The company has made recent acquisitions, including Rx Savings Solutions and plans to acquire a controlling stake in Core Ventures, to strengthen its core operations [3]. Long-Term Growth Targets - McKesson reaffirms its long-term adjusted earnings per diluted share growth target of 12% to 14% and updates the U.S. Pharmaceutical segment's long-term adjusted segment operating profit growth target to 6% to 8% [13][14].

Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Bioventus Inc. will report its financial results for Q1 of fiscal year 2025 on May 6, 2025, before market opening, followed by a conference call for discussion [1] Group 1: Financial Reporting - The financial results for the first quarter of fiscal year 2025 will be announced before the market opens on May 6, 2025 [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Group 2: Conference Call Participation - Participants can join the conference call by dialing 1-833-636-0497 and referencing the Bioventus Inc. Conference Call [2] - A live webcast of the call will be available on the Company's Investor Relations website, with an archive for replay until May 5, 2026 [2] Group 3: Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products for quick and safe healing [3] - The company's mission focuses on helping patients resume active lives through offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Insights - MiMedx Group, Inc. will participate in several industry conferences this quarter to showcase its Advanced Wound Care and Surgical Solutions [1][2] - The company aims to highlight its commitment to innovation and the scientific evidence supporting its products at these conferences [2] Conference Participation - MiMedx will be featured at the Diabetic Limb Salvage (DLS) Conference from April 10-12, 2025, in Washington, D.C., where it will host a sponsored lunch symposium [3] - The company will also participate in the Symposium on Advanced Wound Care (SAWC) Spring 2025 from April 30 to May 4, 2025, in Grapevine, TX, with another sponsored lunch symposium [3] - Additionally, MiMedx will present at Digestive Disease Week (DDW) 2025 from May 3-6, 2025, in San Diego, CA, focusing on the use of amniotic tissues in colorectal surgery [4] Company Overview - MiMedx is recognized as a leader in providing solutions for chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions through innovation [4] - The company has over a decade of experience in the wound care, burn, and surgical sectors of healthcare [4] Conference Details - The DLS Conference emphasizes a multidisciplinary approach to wound healing and limb salvage, featuring an international faculty and promoting evidence-based practices [5] - The SAWC serves as a forum for the entire wound care team to connect and improve patient outcomes through education and advanced clinical reviews [6] - DDW is the largest international gathering in gastroenterology and related fields, showcasing over 4,400 abstracts and hundreds of lectures on the latest advances [7]